Page last updated: 2024-11-07

n-hydroxy-1-(3,4-methylenedioxyphenyl)-2-aminopropane

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

N-hydroxy-1-(3,4-methylenedioxyphenyl)-2-aminopropane: RN given refers to parent cpd [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID98528
CHEMBL ID127313
SCHEMBL ID1742365
MeSH IDM0173395

Synonyms (34)

Synonym
n-hydroxy methylenedioxyamphetamine
CHEMBL127313
n-[1-(1,3-benzodioxol-5-yl)propan-2-yl]hydroxylamine
AKOS006283222
unii-sje1t2b1a7
74698-47-8
n-hydroxy-alpha-methyl-1,3-benzodioxole-5-ethanamine
sje1t2b1a7 ,
n-hydroxy mda
n-hydroxy-3,4-methylenedioxyamphetamine
n-hydroxy-1-(3,4-methylenedioxyphenyl)-2-aminopropane
dea no. 7402
n-oh-mda
1,3-benzodioxole-5-ethanamine, n-hydroxy-alpha-methyl-
114562-59-3
methylenedioxyhydroxyamphetamine
3,4-methylenedioxy-n-hydroxyamphetamine
SCHEMBL1742365
FNDCTJYFKOQGTL-UHFFFAOYSA-N
n-hydroxy-3,4-methylenedioxyamphetamine (n-hydroxy mda)
3,4-methylenedioxy-n-hydroxyamphetamine-
n-hydroxy-mda
mdoh
n-hydroxytenamphetamine
1,3-benzodioxole-5-ethanamine, n-hydroxy-.alpha.-methyl-
mdh (psychedelic)
(+/-)-n(.alpha.-methyl-3,4-(methylenedioxy)phenethyl)hydroxylamine
(+/-)-n-hydroxy-3,4-(methylenedioxy)amphetamine
(+/-)-n-hydroxy-3,4-methylenedioxyamphetamine, analytical standard
Q4043402
(+/-)-n-hydroxy-3,4-methylenedioxyamphetamine
DTXSID30860972
n-hydroxy-3,4-methylenedioxymethamphetamine
(+/-)-n-hydroxy-3 4-methylenedioxyamphe

Research Excerpts

Pharmacokinetics

ExcerptReferenceRelevance
"The metabolism and disposition of N-hydroxy-3,4-methylenedioxyamphetamine (N-OH MDA) was studied by utilizing rat liver slices as well as by intravenous pharmacokinetic studies in rats."( The pharmacokinetics and liver metabolism of N-hydroxy-3,4-methylenedioxyamphetamine (N-OH MDA) in rats.
Brzozowski, D; Clark, CR; Ravis, WR; Valaer, AK, 1994
)
0.29
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Protein Targets (1)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
GLS proteinHomo sapiens (human)Potency70.79460.35487.935539.8107AID624170
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (1)

Assay IDTitleYearJournalArticle
AID91217Compound tested for hallucinogenic activity in humans was reported; Value reported in (A)= Mescaline units1998Journal of medicinal chemistry, Sep-24, Volume: 41, Issue:20
The frontier orbital phase angles: novel QSAR descriptors for benzene derivatives, applied to phenylalkylamine hallucinogens.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (8)

TimeframeStudies, This Drug (%)All Drugs %
pre-19901 (12.50)18.7374
1990's5 (62.50)18.2507
2000's0 (0.00)29.6817
2010's2 (25.00)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 12.74

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index12.74 (24.57)
Research Supply Index2.20 (2.92)
Research Growth Index4.94 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (12.74)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other8 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]